ClinicalTrials.gg
RecruitingNCT06071429ELITE-BTKUpdated Feb 6, 2026

Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease

An interventional study of MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold and Percutaneous Transluminal Angioplasty (PTA) in Chronic Limb-Threatening Ischemia, sponsored by R3 Vascular Inc.. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by R3 Vascular Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.

Planned enrollment
4th of 82
300 · median 38
Started
2025
with 3 others
No phase
38 of 105
8 open now
Primary completion
2028-03
later than 18 of 19 live
Registered
96th of 105
by date

Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 4th largest by planned enrollment of the 82 interventional ones that give a count, is one of 4 that started in 2025, is one of 38 with no phase, reaches primary completion later than 18 of the 19 other live ones, and was the 96th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, or all of them as a file.
02

Study summary

The objective of this prospective, single-blinded, randomized controlled trial is to evaluate the safety and efficacy of the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Approximately 276 subjects will be randomized in a 1:1 ratio. The clinical investigation will be conducted at up to 60 clinical sites globally.

03

Conditions studied

  • Chronic Limb-Threatening Ischemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria

  1. Subject (or their legally authorized representative) has provided written prior to any study-related procedure, using the form approved by the Institutional Review Board / Ethics Committee.
  2. Subject agrees not to participate in any other device or drug study for a period of at least 12 months following the index procedure.

    Note: Questionnaire-based studies, or other studies that are non-invasive and do not require investigational devices or medications are allowed.

  3. Subject has symptomatic chronic limb-threatening ischemia, determined as Rutherford categories 4 or 5.
  4. Subject is ≥ 18 years of age.
  5. Subject agrees to complete all protocol-required follow-up visits, including angiograms.

    Angiographic Inclusion Criteria

  6. Target lesion(s) in the infrapopliteal vessel(s) of the same limb located in any of the following vessels: tibioperoneal trunk (TPT), anterior tibial artery (ATA), posterior tibial artery (PTA), or peroneal artery.
  7. Target lesion(s) must be located in the proximal 2/3 of the native infrapopliteal vessels and at least 10 cm above the tibio-talar joint.

    Note: Up to two (2) target lesions and two different arteries can be treated

  8. All target lesions must be successfully crossed with a guidewire prior to randomization.

    Note: For CTO, retrograde crossing of the lesion is allowed but treatment must be via antegrade.

    Note: The most distal lesion must be treated before treating more proximal lesions.

  9. Distal tibial and pedal runoff for each target lesion must be patent (free of lesions with \< 50% stenosis). If the index vessel is either anterior or posterior tibial artery, outflow must be contiguous with a patent dorsalis pedis or common plantar artery.
  10. Inflow above-the-knee lesions must be treated successfully (\< 30% diameter stenosis by angiography without evidence of distal embolization, thrombus formation, or vessel rupture).

    Note: Inflow lesions may be treated during the index procedure prior to target lesion(s) using the standard of care (including drug-eluting devices), without wiring the target lesion, if possible. Treatment of inflow lesions in the target limb within prior 30 days is also allowed provided the treatment was successful.

    Note: Atherectomy of non-target lesions is not allowed.

  11. Target lesion must have reference vessel diameter is between 2.75 - 3.75 mm by angiography. Vessel size measured by IVUS is highly recommended to verify RVD.
  12. Target lesion(s) is de novo or restenosed ≥ 70% stenosed by angiography. Note: In-stent restenosis is an exclusion criterion.
  13. The total target lesion length among all target lesions must not exceed 11 cm.
  14. Minimum target lesion length must be >14 mm.
  15. Total scaffold length must not exceed 12 cm, and include at least 2 mm of normal vessel from each pre-dilatation border.
  16. The target vessel must not have any other angiographic significant non-target lesions (≥ 50%).
  17. Tandem non-contiguous target lesions are allowed if there is a plaque-free zone of ≥ 2 cm between the lesions. Total lesion lengths must not exceed 11 cm.
  18. Target lesion(s) stenting does not block access to patent main named branches (tibioperoneal trunk (TPT), anterior tibial artery (ATA), posterior tibial artery (PTA), or peroneal artery).
  19. Non-target below-the-knee lesions in non-target vessels must be successfully treated per standard of care prior to randomization without evidence of thrombosis, distal embolization, or vessel rupture.

    Note: Drug-eluting and atherectomy devices for treatment of non-target lesions is not allowed.

  20. Subject has suitable common femoral (contralateral or antegrade ipsilateral) vascular access.

    Note: Retrograde pedal approach is allowed for crossing but not for treatment of target lesion(s).

  21. At least one fully patent below-the-ankle artery (i.e., dorsalis pedis; common with either, lateral, or medial plantar arteries) without hemodynamically significant lesions (≥ 50% diameter stenosis by angiography) must be present in the target limb.

General Exclusion Criteria

Subjects must not meet any of the following general and angiographic exclusion criteria:

  1. Subject with (BMI) \< 18.
  2. Subject is pregnant or nursing. Subjects who plan pregnancy during the clinical investigation follow-up period may not be enrolled.

    Note: Subjects of must have a negative pregnancy test ≤ 28 days prior to the index procedure and agree to use for 6 months.

  3. Estimated \<1 year, in the opinion of the Investigator at the time of enrollment.
  4. Subject is permanently bedridden.
  5. Subject has known or to device materials and their degradants (sirolimus, poly (L-lactide), poly (D, L-lactide), lactic acid, or platinum-iridium) or to study medications (including antiplatelet medications) or to contrast media and who cannot be adequately premedicated.
  6. Subject has planned surgery or procedure necessitating discontinuation of antiplatelet medications within 6 months after the index procedure.
  7. Subject has had revascularization procedure within the target vessel in the previous 3 months
  8. Subject has prior major amputation (above or below the knee or above the ankle) involving the target limb.

    Note: Major amputation of the contralateral limb is allowed.

  9. Subject has planned surgical or endovascular procedure within 6 months following the index procedure.

    Note: A planned minor amputation (toe and/or transmetatarsal amputation in either limb) is allowed. Treatment of inflow lesions in the target limb within prior 30 days is also allowed provided the treatment was successful (\< 30% residual stenosis, no thrombi, distal emboli or vessel rupture).

  10. Subject who has severe ischemia (ABI ≥ 0.39).
  11. Subject who has neuropathic lesion(s) with no ischemic component (wounds or ulcers occur on pressure zones of the foot with or without Type 2 diabetes , deformed foot/toes, hematoma, edema ).
  12. Subject has presence of osteomyelitis or any gangrene above the metatarsal-phalangeal joints, extensive tissue loss with exposed tendons or requiring complex or recurrent surgeries, full thickness heel ulcer, or pure neuropathic ulcers.
  13. Subject with uncontrolled diabetes with > 10%.
  14. Subject has a prior stroke or myocardial infarction within 3 months of the index procedure.
  15. Subject has acute renal failure, severe or end-stage chronic kidney disease ( \< 30 mL/min), or requires dialysis.
  16. Subject has active systemic infection.
  17. Subject is receiving therapy and/or has known immunosuppressive or disease (e.g., , systemic lupus erythematosus, rheumatoid arthritis, severe asthma requiring immunosuppressive medication, etc.).
  18. Subject has active (receiving or scheduled to receive anticancer therapy for malignancy within 1 year prior to or after the index procedure), active blood dyscrasia or coagulation disorder ( count \< 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC \< 3,000 cells/mm3, or \< 8.0 g/dl).
  19. Subject is an incapacitated individual, defined as a person who is mentally ill, mentally handicapped, or an individual without legal authority to control their activities.
  20. Subject has significant comorbid condition(s), or other medical, social, or psychological conditions (such as history of substance abuse, e.g., alcohol, cocaine, heroin, etc.), that in the Investigator's opinion may limit the subject's ability to participate or comply with study instructions and follow-up. This includes subjects with symptomatic COVID-19 infection in the past 2 months or asymptomatic COVID-19 positive test in the past 1 month.

    Angiographic Exclusion Criteria

  21. Angiographic evidence of thromboembolism or atheroembolism in the target or non-target vessel as confirmed by angiography.
  22. Non target lesion located in the popliteal P3 (infrageniculate) segment or treated with atherectomy.
  23. Presence of aneurysm or acute thrombus in the aorta or lower extremity arteries.
  24. Prior below-the-knee bypass in the target limb.
  25. Previously stented lesion(s) or the presence of stents in the target vessel.
  26. Target vessel(s) have distal hemodynamically significant lesions (≥ 50% diameter stenosis by angiography) outside of the allowed treatment zone (presence of non-target lesions in the target vessel is an exclusion criterion).
  27. Lesions (target or non-target) with severe calcification (per PACSS 4 classification).
  28. Unsuccessful treatment of stenosis (≥ 50% stenosis) of in-flow arteries including the P3 segment of the popliteal artery (infrageniculate).
  29. Absence of a patent pedal artery. Absence of contiguous dorsalis pedis or common plantar arteries if the target vessels are anterior or posterior tibial arteries, respectively.
  30. Target lesion location requires bifurcation treatment with scaffolding of both branches (kissing scaffold is not allowed). In case of presence of disease at a bifurcation, one vessel can be treated as target and the other as non-target.
  31. Lesions (target or non-target) in which successful predilatation cannot be achieved.
  32. Planned atherectomy treatment of any target or non-target lesion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    MAGNITUDE BRS

    Participants who receive the MAGNITUDE BRS device will be included in this arm

    Device: MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold

  • Active comparator
    Percutaneous Transluminal Angioplasty (PTA)

    Participants who receive a PTA device will be included in this arm

    Device: Percutaneous Transluminal Angioplasty (PTA)

Interventions

  • DeviceMAGNITUDE Sirolimus-eluting Bioresorbable Scaffold

    CLTI patients treated with MAGNITUDE BRS

  • DevicePercutaneous Transluminal Angioplasty (PTA)

    CLTI patients treated with PTA

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint: Freedom from MALE+POD (Major Adverse Limb Event + Peri-Operative Death)

    Major Adverse Limb Event (MALE) includes above ankle amputation in index limb, major re-intervention on index limb at 6 months and POD includes perioperative (30-day) mortality.

    Time frame: POD at 30 Days and MALE at 6 months

  2. Primary Efficacy Endpoint: Composite of Limb Salvage and Primary Patency

    Composite of Limb Salvage and Primary Patency includes freedom from: above ankle amputation in index limb, 100% total occlusion of target vessel, binary restenosis of target lesion and clinically-driven target lesion revascularization (CD-TLR).

    Time frame: 6 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2028, 34 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 34 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 6, 2023
StartActual
Apr 11, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2032
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06071429
Lead sponsor
R3 Vascular Inc.
Responsible party
Sponsor
First posted
Oct 6, 2023
Start date
Apr 11, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2032 (estimated)
Last update
Feb 6, 2026

Study contacts

Megan Hill, B.S.
Contact
mhill@r3vascular.com
1(904)540-3844
Josh Smale
Contact
jsmale@r3vascular.com
1(480)244-9523‬
Eric Secemsky, MD
principal investigator · Beth Israel Deaconess Medical Center
Marianne Brodmann, MD
principal investigator · Medical University of Graz
Ramon L Varcoe, MD
principal investigator · Prince of Wales Private Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion